ARCHIVES

Republican Contenders Slam FDA Decision In Care Of Boy With Treatable Brain Tumor.

This article is from The Cancer Letter archive.

Vol. 26 No. 05 | February 4, 2000

Download PDF Visit The Full Archive

Related Articles

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

July 30, 2004

FDA To Once Again Review ESA Label To Reflect Results Of Negative Studies.

December 7, 2007

NCI Issues 8 Awards, 12 Feasibility Grants, In New SPORE Program

October 9, 1992

Cyclamate Committee Finds No Proof Of Carcinogenicity

January 23, 1976

Youth Smoking Begins To Decline, NCI Says

April 5, 2002

In Brief: NCI Monograph On Year 2000 Objectives Now Available; Radiation Accident Workshop Planned

October 31, 1986